Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-2004 for prevention of postoperative VTE after elective unilateral total knee arthroplasty
CTR20230519Phase 2Completed
- Sponsor
- Beijing Shengdi Pharmaceutical
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of SHR-2004 in venous thromboembolism (VTE) (3 arms), sponsored by Beijing Shengdi Pharmaceutical. Primary endpoints: Incidence of venous thromboembolism (VTE) and all-cause mortality and Incidence of major bleeding and clinically relevant non-major bleeding. Started Mar 2023; status: completed.
02
Drugs
SHR-2004
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on CTR20230519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230519.